Home / Atropine / United States
US ATC A03BA01 · updated 2 Nov 2026
Atropine shortage in United States
Is there an Atropine shortage in United States?
Yes. As of 2 Nov 2026, 19 Atropine products are reported short in United States, the first since 1 Jan 2012. No return date has been given. Main reason: not stated.
Also short in France, Ireland, Czechia, Sweden. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25) | American Regent, Inc. | 1 Jan 2012 | not given | Not stated |
| US | Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43) | Accord Healthcare Inc. | 1 Jan 2012 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| US | Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20) | Fresenius Kabi USA, LLC | 1 Jan 2012 | not given | Other |
| US | Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10) | Somerset Therapeutics, LLC | 1 Jan 2012 | not given | Not stated |
| US | Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25) | Somerset Therapeutics, LLC | 1 Jan 2012 | not given | Not stated |
| US | Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05) | Hospira, Inc., a Pfizer Company | 1 Jan 2012 | not given | Not stated |
| US | Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25) | American Regent, Inc. | 1 Jan 2012 | not given | Not stated |
| US | Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25) | Somerset Therapeutics, LLC | 1 Jan 2012 | not given | Not stated |
| US | Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10) limited | Hospira, Inc., a Pfizer Company | 1 Jan 2012 | not given | Other |
| US | Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91) | Medefil, Inc. | 1 Jan 2012 | not given | Not stated |
| US | Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08) | Accord Healthcare Inc. | 1 Jan 2012 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| US | Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08) | Accord Healthcare Inc. | 1 Jan 2012 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| US | Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03) discontinuation | Accord Healthcare Inc. | 1 Jan 2020 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90) discontinuation | Accord Healthcare Inc. | 1 Jan 2020 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1) | Amphastar Pharmaceuticals, Inc. | 1 Jan 2020 | not given | Not stated |
| US | Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45) | Accord Healthcare Inc. | 1 Jan 2020 | not given | Not stated |
| US | Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10) | Hikma Pharmaceuticals USA, Inc. | 20 Dec 2023 | not given | Not stated |
| US | Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)" discontinuation | Hospira, Inc., a Pfizer Company | 7 Nov 2025 | not given | Not stated |
| US | Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)" discontinuation | Hospira, Inc., a Pfizer Company | 7 Nov 2025 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).